<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oral Maxillofac Pathol</journal-id><journal-id journal-id-type="iso-abbrev">J Oral Maxillofac Pathol</journal-id><journal-id journal-id-type="publisher-id">JOMFP</journal-id><journal-title-group><journal-title>Journal of Oral and Maxillofacial Pathology : JOMFP</journal-title></journal-title-group><issn pub-type="ppub">0973-029X</issn><issn pub-type="epub">1998-393X</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29391733</article-id><article-id pub-id-type="pmc">5763881</article-id><article-id pub-id-type="publisher-id">JOMFP-21-459</article-id><article-id pub-id-type="doi">10.4103/jomfp.JOMFP_72_16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A study on Evaluation of efficacy of bethanechol in the management of chemoradiation-induced xerostomia in oral cancer patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kavitha</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Mubeen</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Vijayalakshmi</surname><given-names>KR</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1">Department of Oral Medicine and Radiology, Madha Dental College and Hospital, Chennai, Tamil Nadu, India</aff><aff id="aff2"><label>1</label>Department of Oral Medicine and Radiology, Government Dental College and Research Institute, Bengaluru, Karnataka, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. M Kavitha, Department of Oral Medicine and Radiology, Madha Dental College and Hospital, Kundrathur, Chennai - 600 069, Tamil Nadu, India. E-mail: <email xlink:href="kavitha.srnvsn@gmail.com">kavitha.srnvsn@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Dec</season><year>2017</year></pub-date><volume>21</volume><issue>3</issue><fpage>459</fpage><lpage>460</lpage><history><date date-type="received"><day>17</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Journal of Oral and Maxillofacial Pathology</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Objectives:</title><p>Squamous cell carcinoma is the most common oral cancer. Radiotherapy with concomitant chemotherapy is an ideal treatment modality largely used for oral cancers, which precipitates many side effects, of which the most challenging and debilitating side effect is xerostomia. This study aimed to evaluate the efficacy of bethanechol in patients with xerostomia following chemoradiation therapy for oral cancer.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>Fifty patients with xerostomia postchemoradiation therapy, aged between 30 and 65 years, were selected based on selection criteria. Thirty patients in the study group were administered 25 mg bethanechol three times daily (TDS) and 20 patients in the control group with placebo capsules. The subjective symptoms of oral dryness were periodically evaluated at baseline, at the end of 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> weeks using a self-reported questionnaire. Salivary analysis such as whole resting saliva and whole stimulated saliva (WSS) volumes, amylase, pH and sodium potassium ratio were evaluated before and 3 weeks after bethanechol and placebo therapy.</p></sec><sec id="st3"><title>Results:</title><p>Twenty-four (80%) patients in bethanechol group and only 2 (10%) patients in control group showed subjective improvement in oral dryness at the end of 3<sup>rd</sup> week. A significant difference was found between two groups in whole resting and stimulated saliva volume, pH and amylase. However, there was no statistically significant difference in sodium potassium ratio with insignificant adverse effects after 3 weeks of bethanechol therapy.</p></sec><sec id="st4"><title>Conclusions:</title><p>25 mg bethanechol (TDS) has shown subjective improvement in oral dryness in 24 (80%) patients with significant improvement in whole resting and WSS volumes, pH and salivary amylase with insignificant adverse effects.</p></sec></abstract><kwd-group><kwd>Bethanechol</kwd><kwd>oral cancer</kwd><kwd>radiotherapy</kwd><kwd>saliva</kwd><kwd>xerostomia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Squamous cell carcinoma is the most common cancer in the oral cavity, accounting for &#x0003e;90% of all oral cancers.[<xref rid="ref1" ref-type="bibr">1</xref>] It is estimated that annually 70,000&#x02013;80,000 new cases are reported in India. The high incidence of oral cancer in India is attributed to chronic use of tobacco in smoking and smokeless forms.[<xref rid="ref2" ref-type="bibr">2</xref>]</p><p>The mainstay of treatment for oral cancers is surgery, radiotherapy and chemotherapy. However, radiotherapy with concomitant chemotherapy is an ideal nonsurgical treatment modality largely used for oral cancers.[<xref rid="ref3" ref-type="bibr">3</xref>] Radiation of the head and neck precipitates many side effects such as mucositis, dysgeusia, candidiasis and radiation caries. However, the most challenging and debilitating side effect is xerostomia.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>]</p><p>Various treatment strategies such as topical lubricants, coating agents, salivary substitutes, or lozenges have been tried which all provide only a transient relief from xerostomia. However, the most accepted treatment is use of systemic sialogogs, which acts by the stimulation of residual functional salivary gland tissue.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref6" ref-type="bibr">6</xref>]</p><p>Recently, clinical trials on bethanechol, an acetylcholine analog possessing muscarinic cholinergic activity, have reported increase in whole resting and stimulated saliva with minimum side effects in xerostomia patients.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref8" ref-type="bibr">8</xref>] However, at present, there are no studies in India for evaluating the efficacy of bethanechol in patients with xerostomia following chemoradiation therapy. Hence, the need is felt for the study.</p><sec id="sec2-1"><title>Aims and objectives</title><p>
<list list-type="order"><list-item><p>Quantification of whole resting saliva (WRS) and whole stimulated saliva (WSS) volumes and to assess the levels of salivary alpha amylase, sodium potassium ratio and pH in patients with chemoradiation-induced xerostomia in oral cancer before and after bethanechol therapy</p></list-item><list-item><p>To assess the role of bethanechol in the management of xerostomia postchemoradiation therapy in oral cancer patients.</p></list-item></list>
</p></sec></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>The study was conducted in the Department of Oral Medicine and Radiology and consists of fifty xerostomia patients, who underwent chemoradiation therapy for oral cancer. The study was conducted in full accordance with ethical principles and was approved by an institutional ethical board.</p><sec id="sec2-2"><title>Method of collection of data</title><p>Fifty patients with xerostomia, aged between 30 and 65 years, were selected for the study based on set inclusion and exclusion criteria.</p></sec><sec id="sec2-3"><title>Inclusion criteria</title><p>
<list list-type="order"><list-item><p>Patients with histopathologically diagnosed as carcinoma of buccal mucosa, gingivo-buccal sulcus, anterior 2/3<sup>rd</sup> of the tongue, floor of the mouth, gingiva and hard palate [<xref ref-type="fig" rid="F1">Figure 1</xref>]
</p></list-item><list-item><p>Patients who received external beam radiation therapy with Tele-Cobalt 60 to a mean dose of 60&#x02013;70 Gy, over 30&#x02013;35 fractions, 2 Gy/day, 5 fractions a week for 6&#x02013;7 weeks with concurrent chemotherapy, a single agent cisplatin, 40 mg/m<sup>2</sup> intravenous at weekly intervals</p></list-item><list-item><p>Patients with major salivary glands within the radiation portals</p></list-item><list-item><p>Patients with xerostomia immediately following chemoradiation therapy (i.e., WRS &#x0003c;0.1&#x02013;0.2 ml/min and WSS &#x0003c;0.5&#x02013;0.7 ml/min) based on set criteria by Epstein <italic>et al</italic>.[<xref rid="ref7" ref-type="bibr">7</xref>]</p></list-item><list-item><p>Patients with normal liver and renal function.</p></list-item></list>
</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Carcinoma involving anterior alveolus extending into floor of the mouth (ulcero-proliferative type)</p></caption><graphic xlink:href="JOMFP-21-459-g001"/></fig></sec><sec id="sec2-4"><title>Exclusion criteria</title><p>
<list list-type="order"><list-item><p>Patients with carcinomas other than oral cavity</p></list-item><list-item><p>Patients with known allergy to many drugs</p></list-item><list-item><p>Patients with systemic diseases influencing salivary gland and its secretions such as diabetes and renal disease</p></list-item><list-item><p>Patients taking medications such as tri-cyclic anti-depressants, anti-anxiety drugs, anti hypertensives, antihistamines with anti-cholinergic effects</p></list-item><list-item><p>Patients suffering from salivary gland diseases</p></list-item><list-item><p>Patients aged over 65 years.</p></list-item></list>
</p><p>The details of the study were explained to the patients and written informed consents were obtained. A detailed case history was collected and thorough clinical examination was carried out and recorded in specially prepared case history pro forma.</p><p>Patients with xerostomia were divided into two groups:</p><p>
<list list-type="order"><list-item><p>Study group: Thirty patients with xerostomia were subjected to liver and renal function test. Patients with normal liver and renal function were prescribed with bethanechol tablets 25 mg (available with a trade name of URIVOID), orally 3 times daily on empty stomach, 1 h before or 2 h after food to prevent nausea and vomiting for 3 weeks</p></list-item><list-item><p>Control group: Twenty patients with xerostomia were prescribed with placebo capsules containing wheat flour, orally three times daily 1 h before or 2 h after food for 3 weeks.</p></list-item></list>
</p></sec><sec id="sec2-5"><title>Method of collection of salivary sample</title><p>
<list list-type="order"><list-item><p>Patients were called in the morning session between 9 a. m and 11.00 a. m and were made to sit in a comfortable position</p></list-item><list-item><p>Patients were instructed not to drink (except water) or eat 1 h before saliva collection</p></list-item><list-item><p>WRS was collected for 5 min by expectoration into sterile graduated container every 1 min and saliva volumes collected were expressed as ml/min. Patients were instructed not to swallow any saliva during the 5 min collection periods</p></list-item><list-item><p>Stimulated whole saliva was collected after the patient chewed on a standard piece of preweighed paraffin wax (1 g). Collection of saliva was started 1 min after chewing. Patients were asked to spit into a sterile graduated container, once per minute for 5 min and the saliva volumes collected were expressed as ml/min.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref9" ref-type="bibr">9</xref>]</p></list-item></list>
</p><p>The patients in the study were followed up for 3 weeks, and subjective symptoms of oral dryness were periodically evaluated at baseline, at the end of 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> weeks using a self-reported questionnaire designed by Eisbruch <italic>et al</italic>. and Meirovitz <italic>et al</italic>.[<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>] Salivary analysis such as whole resting and stimulated saliva volumes, salivary amylase, sodium potassium ratio and pH were evaluated before and 3 weeks after bethanechol and placebo therapy using standard kit and procedure. Any adverse effects during the treatment period were recorded.</p></sec><sec id="sec2-6"><title>Self-reported questionnaire for evaluation of xerostomia (from baseline to 3 weeks after bethanechol and placebo therapy)</title><p>
<list list-type="bullet"><list-item><p>Rate your difficulty in chewing due to dryness</p></list-item><list-item><p>Rate your difficulty in swallowing solid foods due to dryness</p></list-item><list-item><p>Rate your mouth or throat dryness while not eating</p></list-item><list-item><p>Rate your difficulty in talking due to dryness</p></list-item><list-item><p>Rate the frequency of your sleeping problems due to dryness</p></list-item><list-item><p>Rate the frequency of sipping liquids to aid swallowing food and for oral comfort.[<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>]</p></list-item></list>
</p></sec><sec id="sec2-7"><title>Method of estimation of salivary amylase</title><sec id="sec3-1"><title>Enzymatic colorimetric assay</title><p>Procedure</p><p>The samples and the reagent were brought to room temperature prior to use. 1 in 10 diluted saliva sample (450 &#x003bc;l of distilled water and 50 &#x003bc;l of WRS sample) was added to CoBAS cup. Reagent casettee and CoBAS cup containing saliva sample were inserted in the respective racks in fully automated analyzer (CoBAS Integra 400). The values displayed on monitor were recorded.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref>]</p></sec></sec><sec id="sec2-8"><title>Estimation of salivary sodium</title><sec id="sec3-2"><title>Method (colorimetric method): Sodium estimation comprising two steps</title><p>Step 1: Precipitation of sodium</p><p>
<list list-type="bullet"><list-item><p>Clean dry test tubes were labeled as standard (S) and test (T)</p></list-item><list-item><p>1 ml of precipitating reagent and 0.02 ml of standard were added to test tube (S)</p></list-item><list-item><p>1 ml of precipitating reagent and 0.02 ml of WRS sample were added to test tube (T)</p></list-item><list-item><p>Tubes were mixed well and incubated at room temperature for 5 min and then centrifuged at 2000&#x02013;3000 rpm for 2 min to obtain a clear supernatant.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref>]</p></list-item></list>
</p><p>Step 2: Color development</p><p>
<list list-type="bullet"><list-item><p>Clean dry test tubes were labeled as blank (B), standard (S) and test (T)</p></list-item><list-item><p>1 ml of acid reagent, 0.02 ml of precipitating reagent and 0.1 ml of color reagent were added into the blank tube</p></list-item><list-item><p>1 ml of acid reagent, 0.02 ml of supernatant from step 1 (standard reagent) and 0.1 ml of color reagent were added into the standard tube</p></list-item><list-item><p>1 ml of acid reagent, 0.02 ml of supernatant from step 1 (saliva sample) and 0.1 ml of color reagent were added into the test tube</p></list-item><list-item><p>Test tubes were mixed well and incubated at room temperature for 5 min. Measurement of the absorbance of the blank (Abs. B), standard (Abs. S) and test sample (Abs. T) against distilled water was done within 15 min at 530 nm using colorimeter.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref>]</p></list-item></list>
</p></sec><sec id="sec3-3"><title>Calculations</title><p><inline-graphic xlink:href="JOMFP-21-459-g002.jpg"/></p></sec></sec><sec id="sec2-9"><title>Estimation of salivary potassium</title><p>Procedure: Clean dry test tubes were labeled as blank (B), standard (S) and test (T).</p><p>
<list list-type="bullet"><list-item><p>1 ml of potassium reagent and 0.02 ml of deionized water were added in the blank tube</p></list-item><list-item><p>1 ml of potassium reagent and 0.02 ml of standard reagent were added in the standard tube</p></list-item><list-item><p>1 ml of potassium reagent and 0.02 ml of WRS sample were added in the test tube</p></list-item><list-item><p>Test tubes were mixed well and incubated at room temperature for 5 min. Measurement of the absorbance of the standard (Abs. S) and test sample (Abs. T) against blank was done within 15 min at 630 nm using colorimeter.[<xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref>]</p></list-item></list>
</p><sec id="sec3-4"><title>Calculations</title><p><inline-graphic xlink:href="JOMFP-21-459-g003.jpg"/></p></sec></sec><sec id="sec2-10"><title>Estimation of salivary pH</title><p>The saliva pH was measured using pH indicator strips with a range of 3.5&#x02013;6.0 and 6.5&#x02013;9.0 against the standards assigned by the manufacturer before and 3 weeks after administration of bethanechol and placebo capsules.[<xref rid="ref16" ref-type="bibr">16</xref>]</p><p>The results of the study were statistically analyzed.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><sec id="sec2-11"><title>Age distribution</title><p>The overall mean age in the study sample was found to be 47.74 years.</p></sec><sec id="sec2-12"><title>Gender distribution</title><p>In the study group, 63% of patients were males and 37% of patients were females, whereas in the control group, 60% of patients were males and 40% of were females.</p><p>The subjective symptoms due to oral dryness were evaluated with planned questionnaire designed by Eisbruch <italic>et al</italic>. and Meirovitz <italic>et al</italic>. [Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Evaluation of symptoms of oral dryness in bethanechol group from baseline to 3 weeks assessed using self-reported questionnaire</p></caption><graphic xlink:href="JOMFP-21-459-g004"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Evaluation of symptoms of oral dryness in control group from baseline to 3 weeks assessed using self-reported questionnaire</p></caption><graphic xlink:href="JOMFP-21-459-g005"/></table-wrap></sec><sec id="sec2-13"><title>Whole resting and whole stimulated saliva volume in the study and control groups</title><p>The difference in mean whole resting and WSS volume between the two groups was found to be statistically significant at 3 weeks (<italic>P</italic> &#x0003c; 0.001) [<xref ref-type="table" rid="T3">Table 3</xref> and Graphs <xref ref-type="fig" rid="F2">1</xref> and <xref ref-type="fig" rid="F3">2</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Salivary analysis at baseline and after 3 weeks in bethanechol and control groups</p></caption><graphic xlink:href="JOMFP-21-459-g006"/></table-wrap><fig id="F2" position="float"><label>Graph 1</label><caption><p>Mean whole resting saliva at baseline and after 3 weeks in bethanechol and control groups</p></caption><graphic xlink:href="JOMFP-21-459-g007"/></fig><fig id="F3" position="float"><label>Graph 2</label><caption><p>Mean whole stimulated saliva at baseline and after 3 weeks in bethanechol and control groups</p></caption><graphic xlink:href="JOMFP-21-459-g008"/></fig></sec><sec id="sec2-14"><title>Salivary amylase level in the study and control groups</title><p>The difference in mean salivary amylase level between the two groups was found to be statistically significant at 3 weeks (<italic>P</italic> &#x0003c; 0.001)[<xref rid="ref9" ref-type="bibr">9</xref>] [<xref ref-type="table" rid="T3">Table 3</xref>].</p></sec><sec id="sec2-15"><title>Sodium and potassium concentration in the study and control groups</title><p>The difference in mean salivary sodium potassium ratio between the two groups was not found to be statistically significant at 3 weeks (<italic>P</italic> &#x0003e; 0.05) [<xref ref-type="table" rid="T3">Table 3</xref>].</p></sec><sec id="sec2-16"><title>Salivary pH in study and control groups</title><p>The difference in mean salivary pH between the two groups was found to be statistically significant at 3 weeks (<italic>P</italic> &#x0003c; 0.001) [<xref ref-type="table" rid="T3">Table 3</xref>].</p></sec><sec id="sec2-17"><title>Side effects of bethanechol</title><p>In the study group, three patients reported frequent urination as adverse effect (10%) and only one patient had sweating (3.3%), with overall percentage of adverse reactions of about 13.3% in patients treated with bethanechol.</p></sec></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Bethanechol, a centrally acting parasympathomimetic drug, is currently indicated for the treatment of postoperative and postpartum nonobstructive urinary retention and neurogenic atony of the urinary bladder with retention, which brings about wonderful results with less adverse reactions.[<xref rid="ref7" ref-type="bibr">7</xref><xref rid="ref17" ref-type="bibr">17</xref>]</p><p>Xerostomia associated with radiotherapy for head and neck cancer has its onset during the first 2 weeks, progresses and reaches maximum at the end of 6 weeks.[<xref rid="ref18" ref-type="bibr">18</xref><xref rid="ref19" ref-type="bibr">19</xref>] The salivary quantity drops from the usual normal values of WRS volume of 0.3&#x02013;0.4 ml/min and WSS volume of 1&#x02013;3 ml/min.[<xref rid="ref20" ref-type="bibr">20</xref>] The composition of saliva also shows alterations such as decreased alpha amylase,[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] increased sodium potassium ratio,[<xref rid="ref23" ref-type="bibr">23</xref>] and decreased salivary pH,[<xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref22" ref-type="bibr">22</xref>] against normal values (normal levels of salivary amylase = 27 &#x000b1; 3.8&#x02013;1440 &#x000b1; 160 U/ml,[<xref rid="ref12" ref-type="bibr">12</xref>] sodium potassium ratio = 0.5,[<xref rid="ref24" ref-type="bibr">24</xref>] and pH = 6&#x02013;7).[<xref rid="ref24" ref-type="bibr">24</xref>] There are several ways to clinically assess the signs and symptoms of xerostomia, but the most accepted is self-reported questionnaire designed by Eisbruch <italic>et al</italic>. and Meirovitz <italic>et al</italic>.[<xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref>] Hence, we have used the same in our study.</p><p>The statistically significant increase in WRS and WSS volume in the study group could be explained based on the fact that, after oral administration of bethanechol, it is rapidly absorbed from gastrointestinal tract and pharmacologic effects appear in 30 min, reaching maximum effectiveness in 60&#x02013;90 min and it stimulates functional residual salivary tissues outside the radiation field, chiefly minor glands rather than those glands that were included in the radiation portals, with a duration of action of 6&#x02013;8 h.[<xref rid="ref8" ref-type="bibr">8</xref>]</p><p>The results of our study are similar to results of studies by Epstein <italic>et al</italic>.,[<xref rid="ref7" ref-type="bibr">7</xref>] Gorsky <italic>et al</italic>.,[<xref rid="ref8" ref-type="bibr">8</xref>] Jham <italic>et al</italic>.[<xref rid="ref17" ref-type="bibr">17</xref>] and Chainani-Wu <italic>et al</italic>.[<xref rid="ref25" ref-type="bibr">25</xref>] who also reported significant increases in whole resting and WSS volumes.</p><p>The time taken for acinar regeneration after radiotherapy of oral cancer is found to be 6&#x02013;12 months and hence there was no significant improvement in WRS and WSS after 3 weeks in the control group.[<xref rid="ref18" ref-type="bibr">18</xref>]</p><p>Salivary amylase is an enzyme synthesized primarily in the acinar cells and less consistently in the proximal cells of the intercalated ducts and is a good indicator of the function of salivary glands.[<xref rid="ref26" ref-type="bibr">26</xref>]</p><p>The significant increase in the level of amylase is reported and substantiated by Turner and Sugiya[<xref rid="ref27" ref-type="bibr">27</xref>] by the fact that bethanechol acts on residual acinar cells, causing stimulation of muscarinic receptors, which activates phosphatidylinositide metabolism and induces an increase in intracellular Ca2+ concentration resulting in Ca2+-dependent amylase secretion.</p><p>In our study, increased sodium potassium ratio was observed after radiotherapy (0.78) similar to studies by Ben-Aryeh <italic>et al</italic>.[<xref rid="ref28" ref-type="bibr">28</xref>] and could be due to effect of ionizing radiation on the reabsorption ability of the tubuli. The level of sodium ions in resting saliva did not show significant alteration after bethanechol therapy. The sodium and potassium levels in the saliva depend on the reabsorption ability of the tubuli and tubular secretion, respectively,[<xref rid="ref24" ref-type="bibr">24</xref><xref rid="ref29" ref-type="bibr">29</xref>] and are proportionate to the flow rate.[<xref rid="ref29" ref-type="bibr">29</xref>] Since bethanechol acts on muscarinic cholinergic receptors and increases salivary flow rate, there may be time lapse in reabsorption of sodium from intercalated duct as explained by Case <italic>et al</italic>.[<xref rid="ref29" ref-type="bibr">29</xref>]</p><p>There is an increase in pH values after bethanechol therapy (5.5&#x02013;5.7) which is statistically significant (<italic>P</italic> &#x0003c; 0.001) and may be explained based on increased flow rate and bicarbonate secretion.[<xref rid="ref30" ref-type="bibr">30</xref>] However, there is no significant change in the control group.</p><p>In our study, side effects reported in the bethanechol group were insignificant and only three patients had urinary emergency (10%) and one patient had sweating (3.3%); however, no patient discontinued the drug during 3 weeks of therapy.</p></sec><sec sec-type="conclusions" id="sec1-5"><title>CONCLUSIONS</title><p>This is a preliminary study for evaluating the efficacy of bethanechol in the management of xerostomia in patients treated for oral cancer. The following observations were noted in the study.</p><p>
<list list-type="order"><list-item><p>There was a significant improvement in subjective symptoms of xerostomia in 80% of patients treated with bethanechol</p></list-item><list-item><p>There was a significant increase in the whole resting and stimulated saliva volumes, salivary amylase level and salivary pH in the bethanechol group compared to control group. However, there was no significant change in sodium potassium ratio in patients treated with bethanechol and control groups</p></list-item><list-item><p>There was an insignificant adverse effect in the bethanechol group.</p></list-item></list>
</p><p>Thus, 25 mg bethanechol (TDS) administration in patients undergoing chemo-radiation therapy for oral cancer has shown significant improvement in salivary secretion [Figures <xref ref-type="fig" rid="F4">2</xref> and <xref ref-type="fig" rid="F5">3</xref>]. The results of our study encourage for further studies on large sample size with a follow-up of more than 3 weeks.</p><fig id="F4" position="float"><label>Figure 2</label><caption><p>Appearance of oral mucosa in postirradiated xerostomia patient before bethanechol therapy</p></caption><graphic xlink:href="JOMFP-21-459-g009"/></fig><fig id="F5" position="float"><label>Figure 3</label><caption><p>Intraoral photograph showing moist mucosa after bethanechol therapy</p></caption><graphic xlink:href="JOMFP-21-459-g010"/></fig><sec id="sec2-18"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec id="sec2-19" sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgment</title><p>We would like to express our heartful thanks and acknowledge staffs of Department of Radiotherapy and Biochemistry, Bangalore Medical College and Research Institute, and Victoria Hospital, Bangalore, Karnataka, for extending their help during the conduction of the study.</p></ack><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>S</given-names><suffix>Jr</suffix></name></person-group><article-title>Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge</article-title><source>J Am Dent Assoc</source><year>2001</year><volume>132</volume><issue>Suppl</issue><fpage>7S</fpage><lpage>11S</lpage><pub-id pub-id-type="pmid">11803655</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>MC</given-names></name><name><surname>Carnelio</surname><given-names>S</given-names></name><name><surname>Gudattu</surname><given-names>V</given-names></name></person-group><article-title>Molecular analysis of oral squamous cell carcinoma: A tissue microarray study</article-title><source>Indian J Cancer</source><year>2010</year><volume>47</volume><fpage>166</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">20448381</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>PJ</given-names></name><name><surname>Epstein</surname><given-names>JB</given-names></name><name><surname>Sadler</surname><given-names>GR</given-names></name></person-group><article-title>Oral and dental management related to radiation therapy for head and neck cancer</article-title><source>J Can Dent Assoc</source><year>2003</year><volume>69</volume><fpage>585</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">14653934</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jham</surname><given-names>BC</given-names></name><name><surname>da Silva Freire</surname><given-names>AR</given-names></name></person-group><article-title>Oral complications of radiotherapy in the head and neck</article-title><source>Braz J Otorhinolaryngol</source><year>2006</year><volume>72</volume><fpage>704</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17221065</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hey</surname><given-names>J</given-names></name><name><surname>Setz</surname><given-names>J</given-names></name><name><surname>Gerlach</surname><given-names>R</given-names></name><name><surname>Vordermark</surname><given-names>D</given-names></name><name><surname>Gernhardt</surname><given-names>CR</given-names></name><name><surname>Kuhnt</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of cisplatin on parotid gland function in concomitant radiochemotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2009</year><volume>75</volume><fpage>1475</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">19515505</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JT</given-names></name><name><surname>Ferretti</surname><given-names>GA</given-names></name><name><surname>Nethery</surname><given-names>WJ</given-names></name><name><surname>Valdez</surname><given-names>IH</given-names></name><name><surname>Fox</surname><given-names>PC</given-names></name><name><surname>Ng</surname><given-names>D</given-names></name><etal/></person-group><article-title>Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>390</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8326972</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>JB</given-names></name><name><surname>Burchell</surname><given-names>JL</given-names></name><name><surname>Emerton</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>ND</given-names></name><name><surname>Silverman</surname><given-names>S</given-names><suffix>Jr</suffix></name></person-group><article-title>A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study</article-title><source>Oral Surg Oral Med Oral Pathol</source><year>1994</year><volume>77</volume><fpage>610</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7915026</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorsky</surname><given-names>M</given-names></name><name><surname>Epstein</surname><given-names>JB</given-names></name><name><surname>Parry</surname><given-names>J</given-names></name><name><surname>Epstein</surname><given-names>MS</given-names></name><name><surname>Le</surname><given-names>ND</given-names></name><name><surname>Silverman</surname><given-names>S</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>The efficacy of Pilocarpine and Bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><year>2004</year><volume>97</volume><fpage>190</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14970777</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navazesh</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>SK</given-names></name></person-group><article-title>University of Southern California School of Dentistry. Measuring salivary flow: Challenges and opportunities</article-title><source>J Am Dent Assoc</source><year>2008</year><volume>139</volume><issue>Suppl</issue><fpage>35S</fpage><lpage>40S</lpage><pub-id pub-id-type="pmid">18460678</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meirovitz</surname><given-names>A</given-names></name><name><surname>Murdoch-Kinch</surname><given-names>CA</given-names></name><name><surname>Schipper</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Eisbruch</surname><given-names>A</given-names></name></person-group><article-title>Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>66</volume><fpage>445</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16839705</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisbruch</surname><given-names>A</given-names></name><name><surname>Rhodus</surname><given-names>N</given-names></name><name><surname>Rosenthal</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>B</given-names></name><name><surname>Rasch</surname><given-names>C</given-names></name><name><surname>Sonis</surname><given-names>S</given-names></name><etal/></person-group><article-title>How should we measure and report radiotherapy-induced xerostomia?</article-title><source>Semin Radiat Oncol</source><year>2003</year><volume>13</volume><fpage>226</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12903012</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashok</surname><given-names>L</given-names></name><name><surname>Sujatha</surname><given-names>GP</given-names></name><name><surname>Hema</surname><given-names>G</given-names></name></person-group><article-title>Estimation of salivary amylase and total proteins in leukemia patients and its correlation with clinical feature and radiographic finding</article-title><source>Indian J Dent Res</source><year>2010</year><volume>21</volume><fpage>486</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">21187610</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruse-Jarres</surname><given-names>JD</given-names></name><name><surname>Kaiser</surname><given-names>C</given-names></name><name><surname>Hafkenscheid</surname><given-names>JC</given-names></name><name><surname>Hohenwallner</surname><given-names>W</given-names></name><name><surname>Stein</surname><given-names>W</given-names></name><name><surname>Bohner</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evaluation of a new alpha-amylase assay using 4.6-ethylidene-(G7)-1-4-nitrophenyl-(G1)-alpha-D-maltoheptaoside as substrate</article-title><source>J Clin Chem Clin Biochem</source><year>1989</year><volume>27</volume><fpage>103</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">2787387</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Hirulkar</surname><given-names>NB</given-names></name><name><surname>Ranka</surname><given-names>P</given-names></name></person-group><article-title>Effect of hyperglycemias on electrolytes Imbalance</article-title><source>Int J Pharm Biol Arch</source><year>2011</year><volume>2</volume><fpage>526</fpage><lpage>33</lpage></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Chandrasekar</surname><given-names>T</given-names></name><name><surname>Ramani</surname><given-names>P</given-names></name><name><surname>Anuja</surname></name></person-group><article-title>Determining toothache severity in pediatric patients: A study</article-title><source>J Indian Soc Pedod Prev Dent</source><year>2006</year><volume>24</volume><fpage>140</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17065781</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharevich</surname><given-names>O</given-names></name><name><surname>Shipman</surname><given-names>B</given-names></name><name><surname>Goldman</surname><given-names>BM</given-names></name><name><surname>Nahon</surname><given-names>M</given-names></name></person-group><article-title>Salese to buffer saliva in elderly patients with xerostomia: A pilot study</article-title><source>J Prosthodont</source><year>2011</year><volume>20</volume><fpage>135</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21284764</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jham</surname><given-names>BC</given-names></name><name><surname>Teixeira</surname><given-names>IV</given-names></name><name><surname>Aboud</surname><given-names>CG</given-names></name><name><surname>Carvalho</surname><given-names>AL</given-names></name><name><surname>Coelho Mde</surname><given-names>M</given-names></name><name><surname>Freire</surname><given-names>AR</given-names></name><etal/></person-group><article-title>A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer</article-title><source>Oral Oncol</source><year>2007</year><volume>43</volume><fpage>137</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16798061</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>White</surname><given-names>SC</given-names></name><name><surname>Pharaoh</surname><given-names>MJ</given-names></name></person-group><source>Oral Radiology: Principles and Interpretation</source><year>2011</year><edition>6th ed</edition><publisher-loc>New Delhi</publisher-loc><publisher-name>Reed Elsevier India Private Limited</publisher-name><fpage>18</fpage><lpage>23</lpage></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berk</surname><given-names>LB</given-names></name><name><surname>Shivnani</surname><given-names>AT</given-names></name><name><surname>Small</surname><given-names>W</given-names><suffix>Jr</suffix></name></person-group><article-title>Pathophysiology and management of radiation-induced xerostomia</article-title><source>J Support Oncol</source><year>2005</year><volume>3</volume><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15915820</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawes</surname><given-names>C</given-names></name></person-group><article-title>Salivary flow patterns and the health of hard and soft oral tissues</article-title><source>J Am Dent Assoc</source><year>2008</year><volume>139</volume><issue>Suppl</issue><fpage>18S</fpage><lpage>24S</lpage><pub-id pub-id-type="pmid">18460676</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dreizen</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>LR</given-names></name><name><surname>Handler</surname><given-names>S</given-names></name><name><surname>Levy</surname><given-names>BM</given-names></name></person-group><article-title>Radiation-induced xerostomia in cancer patients. Effect on salivary and serum electrolytes</article-title><source>Cancer</source><year>1976</year><volume>38</volume><fpage>273</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7352</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Barros Pontes</surname><given-names>C</given-names></name><name><surname>Polizello</surname><given-names>AC</given-names></name><name><surname>Spadaro</surname><given-names>AC</given-names></name></person-group><article-title>Clinical and biochemical evaluation of the saliva of patients with xerostomia induced by radiotherapy</article-title><source>Braz Oral Res</source><year>2004</year><volume>18</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">15273790</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MW</given-names></name><name><surname>Izutsu</surname><given-names>KT</given-names></name><name><surname>Rice</surname><given-names>JC</given-names></name></person-group><article-title>Parotid gland pathophysiology after mixed gamma and neutron irradiation of cancer patients</article-title><source>Oral Surg Oral Med Oral Pathol</source><year>1981</year><volume>52</volume><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">6946378</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guyton</surname><given-names>AC</given-names></name><name><surname>Hall</surname><given-names>JE</given-names></name></person-group><source>Textbook of Medical Physiology</source><year>2006</year><edition>11th ed</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Elsevier Inc</publisher-name><fpage>793</fpage><lpage>5</lpage></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chainani-Wu</surname><given-names>N</given-names></name><name><surname>Gorsky</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>P</given-names></name><name><surname>Bostrom</surname><given-names>A</given-names></name><name><surname>Epstein</surname><given-names>JB</given-names></name><name><surname>Silverman</surname><given-names>S</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Assessment of the use of sialogogues in the clinical management of patients with xerostomia</article-title><source>Spec Care Dentist</source><year>2006</year><volume>26</volume><fpage>164</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">16927740</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitra</surname><given-names>S</given-names></name><name><surname>Shyamala Devi</surname><given-names>CS</given-names></name></person-group><article-title>Effects of radiation and alpha-tocopherol on saliva flow rate, amylase activity, total protein and electrolyte levels in oral cavity cancer</article-title><source>Indian J Dent Res</source><year>2008</year><volume>19</volume><fpage>213</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18797097</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>RJ</given-names></name><name><surname>Sugiya</surname><given-names>H</given-names></name></person-group><article-title>Understanding salivary fluid and protein secretion</article-title><source>Oral Dis</source><year>2002</year><volume>8</volume><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">11936453</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Aryeh</surname><given-names>H</given-names></name><name><surname>Gutman</surname><given-names>D</given-names></name><name><surname>Szargel</surname><given-names>R</given-names></name><name><surname>Laufer</surname><given-names>D</given-names></name></person-group><article-title>Effects of irradiation on saliva in cancer patients</article-title><source>Int J Oral Surg</source><year>1975</year><volume>4</volume><fpage>205</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">811576</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>RM</given-names></name><name><surname>Howorth</surname><given-names>AJ</given-names></name><name><surname>Padfield</surname><given-names>PJ</given-names></name></person-group><article-title>Effects of acetylcholine, isoprenaline and forskolin on electrolyte and protein composition of rabbit mandibular saliva</article-title><source>J Physiol</source><year>1988</year><volume>406</volume><fpage>411</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">3254419</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>CJ</given-names></name><name><surname>Young</surname><given-names>JA</given-names></name></person-group><article-title>A microperfusion investigation of the effects of a sympathomimetic and a parasympathomimetic drug on water and electrolyte fluxes in the main duct of the rat submaxillary gland</article-title><source>Pflugers Arch</source><year>1971</year><volume>327</volume><fpage>303</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">5106063</pub-id></element-citation></ref></ref-list></back></article>